Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage study with a small group of healthy participants … ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.
Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...
Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.
Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data ...
Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...
Major cutbacks are planned at NHS England as part of government plans to "avoid duplication" with the Department of Health and Social Care (DHSC). It means around 6,500 jobs are at risk, about ...
NHS England's outgoing chief executive Amanda Pritchard has already resigned Major cutbacks are planned at NHS England as part of government plans to "avoid duplication" with the Department of ...
ServiceNow to Grow in Florida, Will Keep HQ in California Thousands of staff could eventually be based in Florida ServiceNow has explored moving headquarters to West Palm Beach ...
Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...
Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $117.39. The firm’s 50 day moving average is $99.15 and its 200-day moving average is $91.09.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback